北美的動物用藥市場 - 全球產業分析，規模，佔有率，成長，趨勢，預測(2031年)- 各產品，各動物類型，各終端用戶，各國

北美動物用藥市場近年來經歷了穩定成長。這種擴張主要是由於寵物主人對動物健康的認識不斷提高，以及對藥物在治療各動物種疾病方面發揮的重要作用的認識。預計該市場將持續呈上升趨勢，2024年達到14.8億美元，2031年達到27億美元。

推動市場成長的主要因素是寵物主人對寵物健康的意識不斷增強。根據美國寵物產品協會和美國獸醫協會 (AVMA) 的報告，美國約有 8,490 萬個家庭養寵物。越來越多的寵物主人增加了對獸醫護理和針對其特定需求的複合藥物的需求。

仿製藥動物用藥的高價格和容易取得也是促進市場擴張的因素。獲得許可的藥局為那些更喜歡這些藥物而不是更昂貴的品牌藥物的寵物主人提供了更實惠和更方便的選擇。這種趨勢在寵物照護費用過高的低收入家庭中尤其明顯。

本報告提供北美的動物用藥市場相關調查，提供市場概要，以及各產品，各動物類型，各終端用戶，各國趨勢，及市場參與市場企業的競爭趨勢等資訊。

目錄

第1章 摘要整理

第2章 市場概要

• 市場定義和市場區隔
• 市場動態
• 招聘率/使用情形分析- 主要統計
• 價值鏈分析
• 法規Scenario
• 產品的USP分析
• 波特的五力分析
• COVID-19影響分析
• 經濟概要
• 大環境分析

第3章 北美的動物用藥市場預測，2019年～2031年

• 北美的動物用藥市場預測，各產品，金額(10億美元)，2019年～2031年
• 北美的動物用藥市場預測，各動物類型，金額(10億美元)，2019年～2031年
• 北美的動物用藥市場預測，各終端用戶，金額(10億美元)，2019年～2031年
• 北美的動物用藥市場預測，各國，金額(10億美元)，2019年～2031年

第4章 美國的動物用藥市場預測，2019年～2031年

第5章 加拿大的動物用藥市場預測，2019年～2031年

第6章 競爭情形

• 企業市場佔有率分析，2023年
• 競爭儀表板
• 企業簡介
  • Hoye's Pharmacy
  • Vertisis Custom Pharmacy
  • Smith Caldwell Drug Store
  • Sixth Avenue Medical Pharmacy
  • Dougherty Pharmacy
  • Triangle Compounding Pharmacy Inc.,
  • Wedgewood Pharmacy
  • Millers Pharmacy
  • Chiron Compounding Pharmacy
  • MEDS Canadian Compounding Pharmacy
  • Aurora Compounding
  • Pace Pharmacy

第7章 附錄

The North American veterinary compounding pharmacies market has experienced robust growth in recent years. This expansion is largely driven by the increasing awareness among pet owners about animal health and the critical role of compounded medications in treating various conditions in animals. The market is expected to continue its upward trajectory, with a projected size of US$ 1.48 billion in 2024 and US$ 2.7 billion by 2031.

Key Drivers of Market Growth

Increasing Awareness and Pet Ownership

A primary factor propelling market growth is the heightened awareness of pet health among owners. Reports from the American Pet Product Association and the American Veterinary Medical Association (AVMA) indicate that nearly 84.9 million households in the U.S. own pets. This rise in pet ownership has led to a greater demand for veterinary care and compounded medications tailored to specific needs.

Cost and Availability of Generic Veterinary Drugs

The high cost and limited availability of generic veterinary drugs have also contributed to market expansion. Authorized compounding pharmacies provide more affordable and accessible options for pet owners, who often find these medications preferable to expensive branded drugs. This trend is especially notable in low-income households where the cost of animal care can be prohibitive.

Market Segmentation

CNS Agents Leading the Market

The CNS agents segment is anticipated to hold the largest market value, reaching approximately US$ 517.6 million in 2023. CNS medications are crucial for treating conditions such as attention deficit hyperactivity disorder (ADHD) in companion animals, particularly dogs, significantly contributing to market growth.

Companion Animals Dominate the Market

The companion animal segment, driven by the growing humanization of pets and increasing adoption rates, is expected to dominate the market. This segment is projected to hold around 58.7% of the market share.

Oral Formulations Preferred

Oral formulations are the most preferred method of drug administration in the veterinary sector due to their non-invasive nature, ease of administration, and patient compliance. This segment is expected to capture approximately 75.3% of the market share.

Regional Insights

U.S. Market Holds Significant Share

The U.S. is projected to maintain its dominance in the North American vet compounding pharmacies market, holding around 87.9% of the regional market share. The country's robust regulatory environment, expanding pharmaceutical sector, and increasing demand for diverse animal medications are key factors contributing to its leading position.

Canada's Growing Market Share

Canada is expected to hold a market share of around 12.1%. The increasing popularity of pet ownership and heightened awareness of animal healthcare are driving market growth in the country. Additionally, the introduction of new products by major players is bolstering the market.

Competitive Analysis

Leading companies in the North American vet compounding pharmacies market are focusing on expanding their customer base and enhancing their market presence through the development and launch of new and improved medications. The top four companies account for approximately 35.8% of the market share.

Key Developments

In January 2021, the FDA issued a recommendation titled GFI #256, outlining the conditions under which it would not enforce laws against the bulk manufacturing of medications. This recommendation supports the development of necessary antidotes for poisons found in animal food and significant differences between compounded medications and FDA-approved drugs with the same active ingredients.

In October 2020, Virbac introduced STELFONTA, a novel injectable treatment for canine mast cell tumors, the most common form of skin cancer in dogs. This treatment demonstrated a high rate of tumor eradication and marked a significant advancement in veterinary oncology.

Key Market Players Include:

Hoye's Pharmacy

Vertisis Custom Pharmacy

Smith Caldwell Drug Store

Sixth Avenue Medical Pharmacy

Dougherty Pharmacy

Triangle Compounding Pharmacy Inc.

Wedgewood Pharmacy

Millers Pharmacy

Chiron Compounding Pharmacy

MEDS Canadian Compounding Pharmacy

Aurora Compounding

Pace Pharmacy

Victoria Compounding Pharmacy

Pratt's Compounding Pharmacy

People's Choice Pharmacy

Global North America Vet Compounding Pharmacies Market Segmentation:

By Product:

CNS Agents

Anti-Infective Agents

Hormones and Substitutes

Anti-inflammatory Agents

Others

By Animal Type:

Companion Animals

Dogs

Cats

Equine

Others

Livestock Animals

By End User:

Oral

Injectable

Others

By Country:

U.S.

Canada

Table of Contents

1. Executive Summary

• 1.1. North America Vet Compounding Pharmacies Market Snapshot
• 1.2. Future Projections
• 1.3. Key Market Trends
• 1.4. Regional Snapshot, by Value, 2023
• 1.5. Analyst Recommendations

2. Market Overview

• 2.1. Market Definitions and Segmentations
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Market Opportunities
• 2.3. Adoption Rate/Usage Analysis - Key Statistics
• 2.4. Value Chain Analysis
• 2.5. Regulatory Scenario
• 2.6. Product USP Analysis
• 2.7. Porter's Five Forces Analysis
• 2.8. COVID-19 Impact Analysis
  • 2.8.1. Supply
  • 2.8.2. Demand
• 2.9. Economic Overview
  • 2.9.1. World Economic Projections
• 2.10. PESTLE Analysis

3. North America Vet Compounding Pharmacies Market Outlook, 2019 - 2031

• 3.1. North America Vet Compounding Pharmacies Market Outlook, by Product, Value (US$ Bn), 2019 - 2031
  • 3.1.1. Key Highlights
    • 3.1.1.1. CNS Agents
    • 3.1.1.2. Anti-Infective Agents
    • 3.1.1.3. Hormones and Substitutes
    • 3.1.1.4. Anti-inflammatory Agents
    • 3.1.1.5. Others
• 3.2. North America Vet Compounding Pharmacies Market Outlook, by Animal Type, Value (US$ Bn), 2019 - 2031
  • 3.2.1. Key Highlights
    • 3.2.1.1. Companion Animals
      • 3.2.1.1.1. Dogs
      • 3.2.1.1.2. Cats
      • 3.2.1.1.3. Equine
      • 3.2.1.1.4. Others
    • 3.2.1.2. Livestock Animals
• 3.3. North America Vet Compounding Pharmacies Market Outlook, by End User, Value (US$ Bn), 2019 - 2031
  • 3.3.1. Key Highlights
    • 3.3.1.1. Oral
    • 3.3.1.2. Injectable
    • 3.3.1.3. Others
• 3.4. North America Vet Compounding Pharmacies Market Outlook, by Country, Value (US$ Bn), 2019 - 2031
  • 3.4.1. Key Highlights
    • 3.4.1.1. U.S.
    • 3.4.1.2. Canada

4. U.S. Vet Compounding Pharmacies Market Outlook, 2019 - 2031

• 4.1. U.S. Vet Compounding Pharmacies Market Outlook, by Product, Value (US$ Bn), 2019 - 2031
  • 4.1.1. Key Highlights
    • 4.1.1.1. CNS Agents
    • 4.1.1.2. Anti-Infective Agents
    • 4.1.1.3. Hormones and Substitutes
    • 4.1.1.4. Anti-inflammatory Agents
    • 4.1.1.5. Others
• 4.2. U.S. Vet Compounding Pharmacies Market Outlook, by Animal Type, Value (US$ Bn), 2019 - 2031
  • 4.2.1. Key Highlights
    • 4.2.1.1. Companion Animals
      • 4.2.1.1.1. Dogs
      • 4.2.1.1.2. Cats
      • 4.2.1.1.3. Equine
      • 4.2.1.1.4. Others
    • 4.2.1.2. Livestock Animals
• 4.3. U.S. Vet Compounding Pharmacies Market Outlook, by End User, Value (US$ Bn), 2019 - 2031
  • 4.3.1. Key Highlights
    • 4.3.1.1. Oral
    • 4.3.1.2. Injectable
    • 4.3.1.3. Others
  • 4.3.2. BPS Analysis/Market Attractiveness Analysis

5. Canada Vet Compounding Pharmacies Market Outlook, 2019 - 2031

• 5.1. Canada Vet Compounding Pharmacies Market Outlook, by Product, Value (US$ Bn), 2019 - 2031
  • 5.1.1. Key Highlights
    • 5.1.1.1. CNS Agents
    • 5.1.1.2. Anti-Infective Agents
    • 5.1.1.3. Hormones and Substitutes
    • 5.1.1.4. Anti-inflammatory Agents
    • 5.1.1.5. Others
• 5.2. Canada Vet Compounding Pharmacies Market Outlook, by Animal Type, Value (US$ Bn), 2019 - 2031
  • 5.2.1. Key Highlights
    • 5.2.1.1. Companion Animals
      • 5.2.1.1.1. Dogs
      • 5.2.1.1.2. Cats
      • 5.2.1.1.3. Equine
      • 5.2.1.1.4. Others
    • 5.2.1.2. Livestock Animals
• 5.3. Canada Vet Compounding Pharmacies Market Outlook, by End User, Value (US$ Bn), 2019 - 2031
  • 5.3.1. Key Highlights
    • 5.3.1.1. Oral
    • 5.3.1.2. Injectable
    • 5.3.1.3. Others
  • 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Competitive Landscape

• 6.1. Company Market Share Analysis, 2023
• 6.2. Competitive Dashboard
• 6.3. Company Profiles
  • 6.3.1. Hoye's Pharmacy
    • 6.3.1.1. Company Overview
    • 6.3.1.2. Product Portfolio
    • 6.3.1.3. Financial Overview
    • 6.3.1.4. Business Strategies and Development
  • 6.3.2. Vertisis Custom Pharmacy
    • 6.3.2.1. Company Overview
    • 6.3.2.2. Product Portfolio
    • 6.3.2.3. Financial Overview
    • 6.3.2.4. Business Strategies and Development
  • 6.3.3. Smith Caldwell Drug Store
    • 6.3.3.1. Company Overview
    • 6.3.3.2. Product Portfolio
    • 6.3.3.3. Financial Overview
    • 6.3.3.4. Business Strategies and Development
  • 6.3.4. Sixth Avenue Medical Pharmacy
    • 6.3.4.1. Company Overview
    • 6.3.4.2. Product Portfolio
    • 6.3.4.3. Financial Overview
    • 6.3.4.4. Business Strategies and Development
  • 6.3.5. Dougherty Pharmacy
    • 6.3.5.1. Company Overview
    • 6.3.5.2. Product Portfolio
    • 6.3.5.3. Financial Overview
    • 6.3.5.4. Business Strategies and Development
  • 6.3.6. Triangle Compounding Pharmacy Inc.,
    • 6.3.6.1. Company Overview
    • 6.3.6.2. Product Portfolio
    • 6.3.6.3. Financial Overview
    • 6.3.6.4. Business Strategies and Development
  • 6.3.7. Wedgewood Pharmacy
    • 6.3.7.1. Company Overview
    • 6.3.7.2. Product Portfolio
    • 6.3.7.3. Financial Overview
    • 6.3.7.4. Business Strategies and Development
  • 6.3.8. Millers Pharmacy
    • 6.3.8.1. Company Overview
    • 6.3.8.2. Product Portfolio
    • 6.3.8.3. Financial Overview
    • 6.3.8.4. Business Strategies and Development
  • 6.3.9. Chiron Compounding Pharmacy
    • 6.3.9.1. Company Overview
    • 6.3.9.2. Product Portfolio
    • 6.3.9.3. Financial Overview
    • 6.3.9.4. Business Strategies and Development
  • 6.3.10. MEDS Canadian Compounding Pharmacy
    • 6.3.10.1. Company Overview
    • 6.3.10.2. Product Portfolio
    • 6.3.10.3. Financial Overview
    • 6.3.10.4. Business Strategies and Development
  • 6.3.11. Aurora Compounding
    • 6.3.11.1. Company Overview
    • 6.3.11.2. Product Portfolio
    • 6.3.11.3. Financial Overview
    • 6.3.11.4. Business Strategies and Development
  • 6.3.12. Pace Pharmacy
    • 6.3.12.1. Company Overview
    • 6.3.12.2. Product Portfolio
    • 6.3.12.3. Financial Overview
    • 6.3.12.4. Business Strategies and Development

7. Appendix

• 7.1. Research Methodology
• 7.2. Report Assumptions
• 7.3. Acronyms and Abbreviations

List of Region/Countries

• North America
  • U.S.
  • Canada